C1q Binds to CD4+ T Cells and Inhibits the Release of Pro-Inflammatory Cytokines: Role in the Pathogenesis of Systemic Lupus Erythematosus
Open Access
- 8 May 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (10) , 4468
Abstract
The association between C1q deficiency and the development of Systemic Lupus Erythematosus (SLE) is well established. Several studies have shown that deficiency in C1q is associated with failed apoptotic cleanup, leading to SLE progression. However, the magnitude of this correlation indicates that C1q may play a much more complex role in the development of lupus. This study provides further insight into the pathogenesis of SLE by investigating the consequences of the interaction between C1q and CD4+ T-cells in the breakdown of self-tolerance. Since the C1q/C1q receptor interaction is postulated to play a role, we first confirmed the presence of surface-expressed C1q and C1q receptors on CD4+ T-cells. Then, cell proliferation assays were performed in the presence and absence of purified C1q, gC1qR, and cC1qR. The supernatants of these cultures were used to determine the levels of immunoregulatory cytokines released. Our data confirm that increasing concentrations of C1q and gC1qR significantly inhibited cell proliferation. Furthermore, the CD4+ cells treated with either C1q or gC1qR secreted reduced inflammatory cytokines, such as IL-6 and TNF-alpha, compared to the untreated controls, suggesting that C1q deficiency facilitates the uncontrolled secretion of these critical cytokines, thus contributing to SLE. Although the role of pro-inflammatory cytokines in the induction of SLE is well documented, the mechanism by which C1q contributes to the disease is still a study in progress. Our data demonstrate that the interaction between C1q and its receptors on CD4+ T cells plays a critical role in the suppression of pro-inflammatory cytokines that cause tissue injury in SLE. Therefore, the C1q-C1qR axis may provide a rationally sound target for the design of novel therapeutic approaches for SLE treatment.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (RO1 AI 060866, RO1 AI-084178, R56 AI-122376-01A1)
- Stony Brook University (RO1 AI 060866, RO1 AI-084178, R56 AI-122376-01A1)
This publication has 33 references indexed in Scilit:
- Interferon-gamma regulates inflammatory cell death by targeting necroptosis in experimental autoimmune arthritisScientific Reports, 2017
- C1q as an autocrine and paracrine regulator of cellular functionsMolecular Immunology, 2017
- The effects of IL-6 on CD4 T cell responsesClinical Immunology, 2009
- Gut bacteria side-step lymph nodesJournal of Experimental Medicine, 2006
- The classical pathway is the dominant complement pathway required for innate immunity toStreptococcus pneumoniaeinfection in miceProceedings of the National Academy of Sciences, 2002
- C1q, Autoimmunity and ApoptosisImmunobiology, 2002
- gC1q-R/p33: Structure-Function Predictions from the Crystal StructureImmunobiology, 2002
- Links between complement abnormalities and systemic lupus erythematosusRheumatology, 2000
- C1q and Systemic Lupus ErythematosusImmunobiology, 1998
- Interaction of C1q with its receptor on cultured cell lines induces an anti-proliferative responseClinical Immunology and Immunopathology, 1990